 |
Rexahn is founded |
 |
2001 |
 |
|
||||
 |
Archexin® receives FDA Orphan Drug Designation |
2005 |
 |
|
|
||||
|
Dr. Chang H. Ahn is recognized among “Maryland’s 25 CEOs You Need To Know” |
2006 |
|
|
|
||||
|
Archexin® completes Phase I Clinical Trial |
2006 |
|
|
|
||||
|
Rexahn named biotechnology company of the year by the Monte Jade Science and Technology Association, Washington, D.C. |
2007 |
|
|
|
||||
|
Archexin® is designated as one of “100 Great Investigational Drugs” by R&D Directions Magazine |
2007 |
|
|
|
||||
|
Rexahn listed on the American Stock Exchange (AMEX) |
2008 |
|
|
|
||||
|
Zoraxel™ completes Phase IIa Clinical Trial for ED and reports positive preliminary results |
2009 |
|
|
|
||||
|
Partnership with Teva Pharmaceuticals for development of RX-3117 |
2009 |
|
|
|
||||
|
Serdaxin® completes Phase IIa Clinical Trial for MDD and reports positive preliminary results |
2009 |
|
|
|
||||
|
Archexin® is recognized as one of Windhover’s Top 10 Most Promising Oncology Products |
2009 |
|
|
CONTACTS:
Stephanie Ascher
Stern Investor Relations, Inc.
212-362-1200
stephanie@sternir.com
Constantine Theodoropulos
Base Pair Communications
617-401-3116
constantine@basepaircomm.com
Stephanie Ascher
Stern Investor Relations, Inc.
212-362-1200
stephanie@sternir.com
Constantine Theodoropulos
Base Pair Communications
617-401-3116
constantine@basepaircomm.com